We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.00 | 45.00 | 65.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
09/8/2022 18:48 | Tim perhaps you should remove the LSE VRP charts ? Looks like that the shares have flat lined . Today they have been given a shot of Viagra but like Viagra the effect on the share price is waning after a few hours ! | haroldthegreat | |
09/8/2022 13:29 | O/T If is the point. I suspect they will need to go the Verona route and raise Nasdaq funds to see it into trials. The cost to current holders might not be very palatable. | waterloo01 | |
09/8/2022 13:16 | Agreed, but if Synairgen can hitch a ride on a platform study, the funding requirement might be quite a bit lower | timbo003 | |
09/8/2022 13:02 | Indeed, although I suspect most of the early holders, unlike yourself, wouldn't have held through the raisings, placings, delistings etc to get somewhere near the end game. Given where SNG are, it would need a 200m raise, similar to here, and the dilution would be huge. | waterloo01 | |
09/8/2022 12:49 | Yes, good idea Waterloo This one has been a looong wait | timbo003 | |
09/8/2022 12:47 | Just need the second study (ENHANCE-1) to come in positive now and then we are off to the races | timbo003 | |
09/8/2022 12:46 | Well done, I didn't follow this onto Nasdaq. Timbo003, you should post something in the Guild about this as is relevant to SNG and you would give that some perspective | waterloo01 | |
09/8/2022 12:42 | Woosh ! Opened up at $12.2 on Nasdaq | timbo003 | |
09/8/2022 08:58 | Last trade $8.62 on Nasdaq pre-market. | tradertrev | |
09/8/2022 06:58 | Nice to you are still here Tim! It’s been a long ride but looks like we are finally getting somewhere. I must admit that I didn’t expect the results to be anything different, as they targeted the improvements which had already proven successful in previous trials. Just seems like a waste of a number of years coupled with massive dilution along the way. | digger18 | |
09/8/2022 06:36 | Surely not, is somebody fiddling with the controls of the matrix? Looking forward to hearing more about this result (for a change) | timbo003 | |
08/8/2022 21:54 | Phase 3 results of Enhance2 being presented tomorrow! Hopefully a reward for long suffering holders. | digger18 | |
14/7/2022 17:07 | no......just laying low! | haff1 | |
14/7/2022 07:50 | Not dead yet! | tradertrev | |
10/6/2022 08:21 | Ah...the latter ...... as expected ......and consistent with the normal dissappointments here... | haff1 | |
07/6/2022 09:58 | ... a little promise of a better time? ..... or just the quick rise before yet another further fall?... | haff1 | |
15/4/2022 09:58 | ...busy drifting down..... nothing new here..... | haff1 | |
24/2/2022 13:20 | ....busy going no where...... | haff1 | |
22/2/2022 11:15 | ...didn't need one for Covid! | haff1 | |
04/2/2022 09:26 | Hard to speed up a pivotal phase 3 clinical trial! | tradertrev | |
04/2/2022 09:21 | ...the usual slow drawn out dissappointment we are use to here, I note! | haff1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions